Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Binding to the GLP-1 receptor promotes insulin secretion in a glucose-dependent manner, slows gastric emptying, and reduces appetite through central nervous system signaling, aiding in glycemic control and weight loss
Follow aftercare instructions rather than guessing at home
A medical study found that semaglutide can cut the risk of major heart issues or death by 26% compared to a placebo in people with diabetes [10]
[1] [3] Dizziness is a recognised adverse reaction in the Summary of Product Characteristics (SmPCs) for several GLP-1 medications, though the frequency varies between different products
Mechanism & Research Background GLP-3 (RT) (LY3437943) is a 39-amino acid synthetic peptide engineered as a triple-receptor agonist with concurrent activity at the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
(3) HG + GSH (4 mg/mL)
